PARP1 and cancer: Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved cancer drugs designed to exploit synthetic lethality.1 The defects in homologous recombination (HR) repair sensitize cancer cells to PARP inhibitors.